Ant Group pushes wider adoption of AI-enabled smart glasses for mobile payments
The first such payment outside mainland China was recently completed in Hong Kong using Meizu's StarV smart glasses, according to a statement on Thursday by the company, an affiliate of Post owner Alibaba Group Holding.
That transaction was made via AlipayHK, the Hong Kong platform of Ant Group's flagship Alipay app, using Meizu's smart eyewear to scan the QR code and use voice command. The whole process – including voice interface, intent recognition and voice authentication – was powered by Ant's artificial intelligence (AI) system.
The mobile payments functionality shows that proponents of AI glasses are expanding use cases to help broaden the adoption of smart eyewear.
The Ant-Meizu initiative comes days after a similar launch on the mainland by augmented reality (AR) glasses maker Rokid with the Hangzhou-based fintech giant. The Rokid eyewear introduced on Tuesday supports in-store payments by scanning the QR code and confirming payment with a voice command.
'In the coming years, this technology could enable people to complete transactions simply by looking at or gesturing towards a product,' Ant said in an earlier statement on Tuesday.
The latest Ant announcement confirmed a Post interview in April with Meizu owner DreamSmart Group, operated by Chinese auto giant Zhejiang Geely Holding Group. The firm said it was working with Ant International, which was spun off from the fintech company last year, to enable mobile payments via Meizu's smart glasses.
Ant said on Thursday it expected to expand the adoption of smart glasses for payments through its e-wallet partners worldwide. This includes 36 mobile payment apps, including Line Pay and GrabPay, through the Alipay+ network that connects more than 1.7 billion user accounts in 70 markets.
Global shipments of smart glasses, excluding AR eyewear, more than doubled to 1.6 million units in 2024, according to Beijing-based market researcher Runto.
On top of its QR code and facial-recognition functions to facilitate payments, Alipay in June last year introduced its tap-and-pay service on the mainland, enabling consumers to settle transactions by tapping their smartphones on merchant terminals or payment tags.
While that technology is similar to those used by Visa and Apple Pay, the nationwide coverage of Alipay has helped the platform sign up 100 million tap-and-pay users as of April 2025.
Alipay rival WeChat Pay, owned by Tencent Holdings, introduced its palm-recognition payment technology on the mainland in 2023. - SOUTH CHINA MORNING POST
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
3 hours ago
- The Star
Over 100 Chinese enterprises target Zambia's premier show to boost business
LUSAKA, July 25 (Xinhua) -- About 100 Chinese companies are expected to exhibit at the 97th Agricultural and Commercial Show to boost business ties, the Zambia Chinese Association (ZCA) revealed on Friday. The enterprises will showcase their products and services under the Chinese Pavilion organized by the ZCA, during the event scheduled to run from July 30 to August 4 in Lusaka, the Zambian capital. This year's show will be themed "Adapting to Climate Change." ZCA General Secretary Wang Chunyan said the delegation will include about 80 enterprises already operating in Zambia, along with around 20 companies from China's Jiangxi Province. "It is a great platform to support China-Zambia economic cooperation and help Chinese companies grow," Wang said. She noted that the association has participated under the Chinese Pavilion for the past three years, a move that has yielded positive results for participating companies and strengthened business cooperation between China and Zambia. Bernard Moonga, president of the Agricultural and Commercial Cooperative Society of Zambia Limited, the organizer of the event, commended the ZCA for its sponsorship. According to Moonga, China is among the countries with the largest exhibitors at this year's show. The show presents an opportunity for Chinese enterprises to not only showcase their products but also forge new business relationships in Zambia, he added.
Malaysian Reserve
4 hours ago
- Malaysian Reserve
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
INDIANAPOLIS, July 25, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease. 'This acquisition unlocks the opportunity to potentially transform the treatment paradigm for millions of patients worldwide by delivering lifelong cardiovascular risk reduction with a one-and-done treatment,' said Ruth Gimeno, Lilly group vice president, Diabetes and Metabolic Research and Development. 'We are excited to welcome Verve colleagues to Lilly and work together to develop innovative genetic medicines for cardiometabolic disease.' About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram, and LinkedIn. F-LLY Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements regarding Lilly's acquisition of Verve, regarding prospective benefits of the acquisition and Verve's gene editing programs for cardiovascular disease, regarding Verve's product candidates and ongoing clinical and preclinical development, and regarding Lilly's development of programs for cardiovascular disease and advancement of cardiometabolic health medicines. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements reflect current beliefs and expectations; however, these statements involve inherent risks and uncertainties, including with respect to drug research, development and commercialization, Lilly's evaluation of the accounting treatment of the acquisition and its potential impact on its financial results and financial guidance, regulatory changes and developments, the impact of global macroeconomic conditions, including trade and other global disputes and interruptions, including related to tariffs, trade protection measures, and similar restrictions, risks that the acquisition disrupts current plans and operations or adversely affect employee retention, and any legal proceedings that have been or may be instituted related to the acquisition. Actual results could differ materially due to various factors, risks and uncertainties. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the acquisition, that product candidates will be approved on anticipated timelines or at all, that any products, if approved, will be commercially successful, that all or any of the contingent consideration will become payable on the terms described herein or at all, that Lilly's financial results will be consistent with its expected 2025 guidance or that Lilly can reliably predict the impact of the acquisition on its financial results or financial guidance. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the U.S. Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this press release. Refer to: Ashley Hennessey; gentry_ashley_jo@ 317-416-4363 (Media) Michael Czapar; czapar_michael_c@ 317-617-0983 (Investors)
The Sun
7 hours ago
- The Sun
Tesla tops Chinese rivals in assisted driving tests
BEIJING: Billionaire Elon Musk's Tesla outperformed Chinese rivals including BYD, Xiaomi and Huawei in a test of assisted driving technologies on China's highways, according to results published by TikTok owner Bytedance's auto unit Dcar. State television CCTV and Dcar jointly tested the level 2 advanced driving assistance systems (ADAS) from more than 20 electric vehicle brands in China and rated their performance in a series of scenarios with higher risks of accidents on highways and urban traffics. The test videos posted by Dcar went viral on Chinese social media. Tesla scored the best in the highway test among 36 models, with its Model 3 and Model X passing five out of six scenarios, while BYD's Denza Z9GT and Huawei-backed Aito M9 failed in three scenarios. Xiaomi's SU7 passed in one of six. In a Weibo post on Friday, HIMA, the Huawei-led auto alliance, said it declined to comment on the 'so-called test.' BYD and Xiaomi didn't immediately respond to requests for comment. 'Due to laws against data export, Tesla achieved the top results in China despite having no local training data,' Tesla CEO Elon Musk said on his X account on Friday. Tesla has been caught in what Musk described as a 'quandary', as the U.S. doesn't allow its AI software to be trained in China, while the automaker has been seeking approval from Chinese regulators to transfer data saved locally in Shanghai back to the United States for algorithm training. Domestic brands should face up to the gap with Tesla in autonomous driving, Wang Yao, deputy chief engineer of the China Association of Automobile Manufacturers, told an auto forum in Shanghai earlier this month. Xiaomi CEO Lei Jun, in remarks after a Tesla Model Y delivered itself from an Austin, Texas factory to its owner in the area roughly 30 minutes away, said 'we will continue to learn' from Tesla which has led industry trends. The test came amid growing safety concerns in China about the ADAS after a highway accident involving a Xiaomi SU7 killed three people in March. State media have blamed misleading promotions for resulting drivers' improper uses of the technologies and the authorities have banned the uses of terms such as 'smart driving' and 'autonomous driving' for marketing driving assistance features. The public security ministry said this week that the country will set out legal responsibilities related to the technology that has yet achieved true autonomous driving. Drivers face safety and legal risks if they are distracted in accidents when assisted driving is turned on, the ministry warned. Xiaomi had seen a slump in new EV orders as a consumer backlash began in April following the fatal trash, but the impact seems short-lived, with its new electric SUV receiving exceptionally strong initially orders after it went on sale last month. Tesla's sales of its China-made electric vehicles edged up 0.8% in June from a year earlier, snapping an eight-month losing streak, but they continued to fall on a quarterly basis in the face of lower-cost new models from its Chinese rivals. Tesla's assisted driving suite is available in China for nearly $9,000, while the technology from its local rivals including Xiaomi and BYD is without extra cost, pressuring the U.S. automaker's self-driving future. Tesla's technology approach relies solely on cameras as sensors and artificial intelligence while most Chinese peers including BYD use lidar (light detection and range sensors) additionally to ensure performance. ($1 = 7.1624 Chinese yuan renminbi) - Reuters
